Exclusion and enrollment summary from NHANES. by Lu Han (151620)

“…Individuals under 30 showed no significant differences. A unit increase below 9.30 in Log2-PMR reduced HCV risk by 0.60-fold. …”

The epidemiology and gene mutation characteristics of pyrazinamide-resistant <i>Mycobacterium tuberculosis</i> clinical isolates in Southern China by Nan Wang (21935)

“…This difference in the <i>rpsA</i> mutation rate was statistically significant (<i>P = 0.001</i>, chi-square test). …”

Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer by Jiaxing Li (113609)

“…Herein, we reported an effective and selective PRMT7 inhibitor, <b>A33</b>, which was obtained through structural optimization and exhibited potent anti-PCa efficacy in vitro and in vivo. …”

Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer by Jiaxing Li (113609)

“…Herein, we reported an effective and selective PRMT7 inhibitor, <b>A33</b>, which was obtained through structural optimization and exhibited potent anti-PCa efficacy in vitro and in vivo. …”

Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer by Jiaxing Li (113609)

“…Herein, we reported an effective and selective PRMT7 inhibitor, <b>A33</b>, which was obtained through structural optimization and exhibited potent anti-PCa efficacy in vitro and in vivo. …”

Development of Novel PRMT7 Inhibitors for the Treatment of Prostate Cancer by Jiaxing Li (113609)

“…Herein, we reported an effective and selective PRMT7 inhibitor, <b>A33</b>, which was obtained through structural optimization and exhibited potent anti-PCa efficacy in vitro and in vivo. …”

Data Sheet 1_Valve-in-valve transcatheter aortic valve replacement (TAVR) leads to lower device success compared to TAVR in native stenosis.pdf by Michael Paukovitsch (16428786)

“…The overall rate of device success amounted to 66% in ViV-TAVR, compared to 96.1% in TAVR (p < 0.01) and ViV-TAVR was independently associated with reduced device success (OR: 0.07, 95%CI: 0.045–0.12, p < 0.01) in multivariate regression. While ViV-TAVR decreased peak and mean gradients significantly, in 31% of patients elevated mean gradients (≥20 mmHg) were observed at discharge. …”

Olfactory function test graphical summary and results. by Myeongguk Jeong (16386165)

(A) Classification of up-regulated DEGs based on GO; (B)Classification of down-regulated DEGs based on GO; (C) KEGG enrichment bubble map of up-regulated DEGs; (D) KEGG enrichment... by Bingshuo Shi (21485387)

Immunohistochemical staining results for OMP in olfactory bulb. by Myeongguk Jeong (16386165)

Western blotting for OMP expression using olfactory bulb and olfactory epithelium. by Myeongguk Jeong (16386165)

Assessment of calcium events, pERK levels, NMDA receptor expression and extracellular zinc levels in <i>slc13a5</i> mutants. by Deepika Dogra (21072023)

“…Voxels exhibiting significantly higher intensity values of pERK are denoted in green and those exhibiting significantly lower pERK intensity values are depicted in magenta, in the <i>slc13a5</i> mutants compared to WTs at 5 dpf. …”

Safranin O fast green staining results of cartilage tissue in different groups of rat PTOA (A: normal group, B: mild PTOA group, C: severe PTOA group). by Peng-fei Han (694841)

Image 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 4_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 2_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.docx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 3_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Table 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.xlsx by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”

Image 1_Endolysin significantly improves symptoms with atopic dermatitis: bridging the gap from research to clinical practice.jpeg by Ling Kui (6108440)

“…Compared to baseline, EASI, SCORAD, IGA, VAS, and DLQI scores demonstrated significant decreases at both Day 7 and Day 14 (all P < 0.05). …”